References
- Garratty G. Predicting the clinical significance of alloantibodies and determining the in vivo survival of transfused red cells. In: Judd WJ, Barnes A, eds. Clinical and serological aspects of transfusion reactions: a technical workshop. Washington, DC: American Association of Blood Banks, 1982:91-119.
- Zupanska B. Cellular immunoassays and their use for predicting the clinical significance of antibodies.In:Garratty G,ed.Immunobiology of transfusion medicine. New York: Dekker, 1994:465-91.
- Englefriet CP, Overbeeke MAM, Dooren MC, Ouwehand WH,von dem Borne AEGKr. Bioassays to determine the clinical significance of red cell alloantibodies based on Fc receptor-induced destruction of red cells sensitized by IgG. Transfusion 1994;34:617-26.
- Hadley AG.A comparison of in vitro tests for predicting the severity of haemolytic disease of the fetus and newborn. Vox Sang 1998;74(Suppl. 2): 375-83.
- Mollison PL. Determination of red cell survival using 51Cr. In: Bell CA, ed. A seminar on immune-mediated cell destruction. Washington, DC: American Association of Blood Banks, 1981:45-69.
- Silvergleid AJ, Wells RF, Hafleigh EB, et al. Compatibility test using 51chromium-labeled red blood cells in crossmatch positive patients. Transfusion 1978;18:8-14.
- Garratty G. Factors affecting the pathogenicity of red cell auto- and alloantibodies. In: Nance SJ, ed. Immune destruction of red blood cells. Arlington, VA: American Association of Blood Banks, 1989: 109-69.
- Hadley AG, Kumpel BM, Merry AH. The chemiluminescent response of human monocytes to red cells sensitized with monoclonal anti-Rh(D) antibodies. Clin Lab Haematol 1988;10:377-84.
- Garratty G,Arndt P, Nance S.IgG subclass of blood group alloantibodies to high frequency antigens (abstract).Transfusion 1996;36:50S.10.Engelfriet CP, Reesink HW. Laboratory procedures for the prediction of the severity of haemolytic disease of the newborn.Vox Sang 1995;69:61-9.
- Judd WJ. Practice guidelines for prenatal and perinatal immunohematology, revisited. Transfusion 2001;41:1445-52.
- International Committee for Standardization in Haematology. Recommended method for radioisotope red-cell survival studies. Br J Haematol 1980; 45:659-66.
- Mollison PL. Survival in vivo as a test for red cell compatibility. Haematologia 1972;6:139-45.
- Nance SJ,Arndt P,Garratty G. Predicting the clinical significance of red cell alloantibodies using a monocyte monolayer assay.Transfusion 1987;27:449-52.
- Davey RJ, Esty SS, Chin JF,Mallory D.A comparison of the monocyte monolayer assay with 51chromium red cell recovery for determining the clinical significance of red cell alloantibodies. Immunohematology 1994;10:90-4.
- Schanfield MS, Stevens JO, Bauman D.The detection of clinically significant erythrocyte alloantibodies using a human mononuclear phagocyte assay. Transfusion 1981;21:571-6.
- Urbaniak SJ, Greiss MA, Crawford RJ, Fergusson MJC. Prediction of the outcome of Rhesus haemolytic disease of the newborn: Additional information using an ADCC assay. Vox Sang 1984; 46:323-9.
- Engelfriet CP, Ouwehand WH. ADCC and other cellular bioassays for predicting the clinical significance of red cell alloantibodies. Baillieres Clin Haematol 1990;3:321-37.
- Nance SJ, Nelson JM, Horenstein J,et al. Monocyte monolayer assay: an efficient noninvasive technique for predicting the severity of hemolytic disease of the newborn. Am J Clin Pathol 1989;92: 89-92.
- Larson PJ, Thorp JM, Miller RC, Hoffman M.The monocyte monolayer assay: a noninvasive technique for predicting the severity of in utero hemolysis. Am J Perinatol 1995;12:157-60.
- Hadley A, Wilkes A, Poole J, Arndt P, Garratty G.A chemiluminescence test for predicting the outcome of transfusing incompatible blood. Transfus Med 1999;9:337-42.
- Garratty G,Arndt P. Determining the clinical significance of blood group alloantibodies: a reevaluation of the interpretation of monocyte monolayer assay results (abstract). Blood 1998;92:563a.
- Garratty G. Evaluating the clinical significance of blood group alloantibodies that are causing problems in pretransfusion testing. Vox Sang 1998; 74(Suppl. 2):285-90.
- Garratty G, Arndt P, Nance S.The potential clinical significance of blood group alloantibodies to high frequency antigens. Blood 1997;90(Suppl 1):473a.
- Sacks DA, Nance SJ, Garratty G,et al. Monocyte monolayer assay as a predictor of severity of hemolytic disease of the fetus and newborn.Am J Perinatol 1993;10:428-31.
- Garner SF, Gorick BD, Lai WYY, et al. Prediction of the severity of haemolytic disease of the newborn. Vox Sang 1995;68:169-76.
- Lucas GF, Hadley AG, Nance SJ, Garratty G. Predicting hemolytic disease of the newborn: a comparison of the monocyte monolayer assay and the chemiluminescence test. Transfusion 1993; 33:484-7.
- Zupanska B, Lenkiewicz B, Michalewska B, Rokicki T.The ability of cellular assays to predict the necessity for cordocenteses in pregnancies at risk of haemolytic disease of the newborn (letter). Vox Sang 2001;80:234.
- Oepkes D,van Kamp IL, Simon MJG, et al. Clinical value of an antibody-dependent cell-mediated cytotoxicity assay in the management of Rh D alloimmunization. Am J Obstet Gynecol 2001;184: 1015-20.
- Garratty G. Predicting the clinical significance of red cell antibodies with in vitro cellular assays. Transfus Med Rev 1990;IV:297-312.